Navigation Links
BioElectronics' Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
Date:1/19/2012

FREDERICK, Md., Jan. 19, 2012 /PRNewswire/ -- BioElectronics Corporation. (OTC-PINK: BIEL), the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced the acceptance for publication of an article in the peer reviewed journal The Journal of Foot and Ankle Surgery. The article documents the clinical trial results of BioElectronics' study of its medical device on plantar fasciitis.

Plantar fasciitis, or heel pain, is a very common complaint which affects up to two million people in the United States yearly, in a multi-million dollar treatment market. Plantar fasciitis heel pain, with the current treatment options, can persist up to one or two years and can be extremely painful and debilitating. 

"With this published clinical trial, which was a placebo controlled, randomized and double blind study, BioElectronics is demonstrating that its patented pulsed radiofrequency electromagnetic field therapy medical device offers a rapid and economical resolution of the heel pain, and consequently is a significant advancement over current treatment options," said Ian Rawe, PhD, BioElectronics Director of Clinical Research. "The publication of these results will help introduce to the medical community a drug-free treatment featuring our unique medical device as an orthopedic pain therapy. We anticipate strong interest which will lead to expanded clinical study on a variety of orthopedic conditions." 

BioElectronics is currently conducting a second clinical study on plantar fasciitis using its revolutionary 'Smart Insole,' which provides a simple, 24-hour treatment option. With this new study, BioElectronics anticipates that it is moving toward making its therapy the treatment of choice in people suffering from plantar fasciitis.

About BioElectronics Corporation

BioElectronics is an award winning medical device developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:
Paul Knopick
E & E Communications
(949) 707-5365
pknopick@eandecommunications.com

 

 

 


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Corporation to Webcast, Live, at RetailInvestorConferences.com on October 6th
2. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
3. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
4. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
5. BioElectronics Announces Major Clinical Trials
6. Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation
7. Incisive Surgical Announces Breakthrough Peer Review Clinical Study
8. Public Policy Staffing Study Offers Benchmark Opportunity for Bio-Pharma and Medical Device Companies
9. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
11. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 BioNovus ... Center,s Institute for Advancing Medical Innovation (IAMI) today ... new drugs, diagnostics and medical devices. ... Innovations with rights to license, develop and commercialize ... "This partnership represents a significant ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)...  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease ... ... ... ... ...
Breaking Medicine Technology:
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Sue Desmond-Hellmann, ... Class of 2016 to stretch the limits of human possibility in her keynote address ... p.m. in the Georgia Dome. , Drawing on her rich experience as a scientist, ...
(Date:5/3/2016)... ... , ... Calvary Hospital recently hosted a reception to mark a new music ... at Mary, Manning Walsh Home (MMW) in Manhattan. , During the school year, ... hour, once a week. The music brings a lot of joy to the patients, ...
(Date:5/3/2016)... NJ (PRWEB) , ... May 03, 2016 , ... ... BCBSNJ) today announced that it has been honored as one of the nation’s ... the 2016 InformationWeek Elite 100. Horizon received the recognition for technology achievements that ...
(Date:5/3/2016)... Springs, FL (PRWEB) , ... May 03, 2016 ... ... nation’s leading innovative specialty pharmacies, will be represented at the 2016 Asembia ... Las Vegas. The Asembia Summit is the largest U.S. health care conference for ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean ... launching a new client service center in La Vergne, Tennessee, near Nashville. The ... the full range of Empyrean client services. , “Our Nashville-area center allows us ...
Breaking Medicine News(10 mins):